Nano-X Imaging Ltd.

NNOX

Equity

ISIN IL0011681371 / Valor 56410599

NASDAQ (2025-11-17)

USD 2.83-4.71%

Nano-X Imaging Ltd.
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Nano-X Imaging Ltd. is a NASDAQ-listed medical imaging company dedicated to making advanced diagnostic technologies more affordable and accessible, thereby promoting preventive healthcare. The company leverages its proprietary digital X-ray source and artificial intelligence to offer a comprehensive ecosystem that includes the Nanox.ARC Digital Tomosynthesis system, which provides cost-effective and user-friendly imaging, and Nanox.AI, which enhances CT scans by identifying early signs of chronic diseases. Additionally, Nano-X provides Nanox.CLOUD, a cloud-based platform for managing and analyzing imaging data, and Nanox.MARKETPLACE, a decentralized service that connects users with radiology and cardiology experts through teleradiology services. By integrating these technologies, Nano-X aims to streamline the imaging process from scan to diagnosis, improve early detection and treatment, and ultimately enhance health outcomes on a global scale.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

The company generated $3.0 million in revenue for Q4 2024, an increase from $2.4 million in the same quarter of 2023, driven by teleradiology services, imaging product sales, and AI solutions.

Regulatory Achievements

Nano-X secured FDA general use clearance for the Nanox.ARC in December 2024 and obtained the CE Mark in the EU in February 2025, with the Nanox.ARC X also submitted for 510(k) FDA clearance.

Commercialization Advances

The company expanded its global footprint by signing new customer and channel partner agreements for Nanox.ARC and Nanox AI, including partnerships in Romania and Greece, marking initial entry points into the EU market.

Financial Performance

Despite a net loss of $14.1 million for Q4 2024 compared to $10.2 million in Q4 2023, Nano-X improved its non-GAAP net loss to $10.0 million. Revenue from teleradiology services increased to $2.8 million, reflecting enhanced customer retention and service volume.

Shareholder Equity

As of December 31, 2024, Nano-X had approximately 63.8 million shares outstanding, up from 57.8 million the previous year, bolstered by a Controlled Equity Offering that raised approximately $37.8 million.

Summarized from source with an LLMView Source

Key figures

-51.6%1Y

-75.8%3Y

-92.5%5Y

Performance

70.5%1Y

87.1%3Y

89.3%5Y

Volatility